TALK vs TBPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
TALK presents a classic growth-vs-value conflict. While the Piotroski F-Score of 4/9 indicates stable financial health and the company has successfully transitioned to profitability with explosive earnings growth (181% YoY), the valuation is disconnected from deterministic baselines. The stock trades at $5.18, significantly exceeding both the Graham Number ($0.79) and Intrinsic Value ($1.18), suggesting a massive growth premium. Strong liquidity (Current Ratio 6.38) offsets the lack of an Altman Z-Score, but bearish insider activity and a weak technical trend temper the bullish growth narrative.
TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.
Compare Another Pair
Related Comparisons
TALK vs TBPH: Head-to-Head Comparison
This page compares Talkspace, Inc. (TALK) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.